(Q34296734)

1 August 2017

1 reference

title

Comparative pharmacokinetics and pharmacodynamics of the rifamycin antibacterials (English)

1 reference

1 August 2017

1 reference

1 reference

Burman WJ

1 reference

1 August 2017

Gallicano K

series ordinal

1 reference

1 August 2017

Peloquin C

series ordinal

1 reference

1 August 2017

language of work or name

1 reference

1 January 2001

1 reference

Clinical Pharmacokinetics

1 August 2017

published in

1 reference

1 August 2017

1 reference

1 August 2017

1 reference

1 August 2017

page(s)

327-341

1 reference

Activity in vitro of rifabutin, FCE 22807, rifapentine, and rifampin against Mycobacterium microti and M. tuberculosis and their penetration into mouse peritoneal macrophages

1 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2165%2F00003088-200140050-00002

Antituberculosis activity of once-weekly rifapentine-containing regimens in mice. Long-term effectiveness with 6- and 8-month treatment regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003088-200140050-00002

Adverse events associated with high-dose rifabutin in macrolide-containing regimens for the treatment of Mycobacterium avium complex lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003088-200140050-00002

Evaluation of the Antiviral Effect of Rifabutin in AIDS-Related Complex

21 January 2018

1 reference

https://api.crossref.org/works/10.2165%2F00003088-200140050-00002

Comparative bioavailability of isoniazid, rifampin, and pyrazinamide administered in free combination and in a fixed triple formulation designed for daily use in antituberculosis chemotherapy. II. Two-month, daily administration study

21 January 2018

1 reference

12 December 2020

Bioavailability of Chinese rifapentine during a clinical trial in Hong Kong

1 reference

12 December 2020

In vitro properties of rifapentine (MDL473) relevant to its use in intermittent chemotherapy of tuberculosis

1 reference

12 December 2020

Uptake and activity of rifapentine in human peritoneal macrophages and polymorphonuclear leukocytes.

1 reference

12 December 2020

Therapeutic implications of drug interactions in the treatment of human immunodeficiency virus-related tuberculosis

1 reference

12 December 2020

Comparison of daily and twice-weekly regimens to treat pulmonary tuberculosis

1 reference

12 December 2020

Effect of preparation method and storage on rifampin concentration in suspensions

1 reference

12 December 2020

Pharmacokinetic interaction between ritonavir and indinavir in healthy volunteers

1 reference

12 December 2020

Bioavailability of rifampicin capsules.

1 reference

12 December 2020

Rifabutin for the treatment of newly-diagnosed pulmonary tuberculosis: a multinational, randomized, comparative study versus Rifampicin. Rifabutin Study Group

1 reference

12 December 2020

Pharmacokinetic study of intravenous rifampicin

1 reference

12 December 2020

The effect of antipyrine and rifampin on the metabolism of diazepam.

1 reference

12 December 2020

Intravascular hemolysis and acute renal failure following intermittent rifampin therapy

1 reference

12 December 2020

Absorption, disposition and preliminary metabolic pathway of 14C-rifabutin in animals and man.

1 reference

12 December 2020

Interaction between rifampin and levothyroxine

1 reference

12 December 2020

The bioavailability of isoniazid, rifampin, and pyrazinamide in two commercially available combined formulations designed for use in the short-course treatment of tuberculosis

1 reference

12 December 2020

Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids

1 reference

12 December 2020

Low serum levels of oral antimycobacterial agents in patients with disseminated Mycobacterium avium complex disease

1 reference

12 December 2020

Disposition and metabolism of 14C-rifapentine in healthy volunteers

1 reference

12 December 2020

Minimal inhibitory concentrations of rifabutin, ciprofloxacin, and ofloxacin against Mycobacterium tuberculosis isolated before treatment of patients in Taiwan

1 reference

12 December 2020

A pilot study of antituberculosis combinations comparing rifabutin with rifampicin in the treatment of HIV-1 associated tuberculosis. A single-blind randomized evaluation in Ugandan patients with HIV-1 infection and pulmonary tuberculosis

1 reference

12 December 2020

Six-month supervised intermittent tuberculosis therapy in Haitian patients with and without HIV infection

1 reference

12 December 2020

The effect of multiple doses of ritonavir on the pharmacokinetics of rifabutin

1 reference

12 December 2020

The pharmacokinetics of oral rifampicin in AIDS patients

1 reference

12 December 2020

Studies on the treatment of tuberculosis undertaken by the British Medical Research Council tuberculosis units, 1946-1986, with relevant subsequent publications

1 reference

12 December 2020

Short-course Chemotherapy for Tuberculosis with Largely Twice-weekly Isoniazid-Rifampin

1 reference

12 December 2020

Clinical pharmacokinetics of rifabutin.

1 reference

12 December 2020

Determination of minimal inhibitory concentrations of antituberculosis drugs by radiometric and conventional methods

1 reference

12 December 2020

Rifapentine and isoniazid in the continuation phase of treating pulmonary tuberculosis. Initial report

1 reference

12 December 2020

A 62-dose, 6-month therapy for pulmonary and extrapulmonary tuberculosis. A twice-weekly, directly observed, and cost-effective regimen

1 reference

12 December 2020

Lack of effect of concomitant zidovudine on rifabutin kinetics in patients with AIDS-related complex

1 reference

12 December 2020

A phase I evaluation of concomitant rifabutin and didanosine in symptomatic HIV-infected patients

1 reference

12 December 2020

Lessons learned from animal models of osteomyelitis

1 reference

12 December 2020

Rifampin-associated thrombocytopenia secondary to poor compliance

1 reference

12 December 2020

Chronic osteomyelitis caused by Staphylococcus aureus: controlled clinical trial of nafcillin therapy and nafcillin-rifampin therapy

1 reference

12 December 2020

Comparative effects of rifabutin and rifampicin on cytochromes P450 and UDP-glucuronosyl-transferases expression in fresh and cryopreserved human hepatocytes.

1 reference

12 December 2020

Metabolism of rifabutin and its 25-desacetyl metabolite, LM565, by human liver microsomes and recombinant human cytochrome P-450 3A4: relevance to clinical interaction with fluconazole

1 reference

12 December 2020

A comparative study of daily followed by twice or once weekly regimens of ethambutol and rifampicin in retreatment of patients with pulmonary tuberculosis. The results at 1 year. A cooperative tuberculosis chemotherapy study in Poland

1 reference

12 December 2020

Clarithromycin or rifabutin alone or in combination for primary prophylaxis of Mycobacterium avium complex disease in patients with AIDS: A randomized, double-blind, placebo-controlled trial. The AIDS Clinical Trials Group 196/Terry Beirn Community

1 reference

12 December 2020

Isolation and identification of major urinary metabolites of rifabutin in rats and humans

1 reference

12 December 2020

Pharmacokinetics of rifabutin in HIV-infected patients with or without wasting syndrome

1 reference

12 December 2020

Pharmacokinetics of rifabutin

1 reference

12 December 2020

Varying dosages of rifabutin affect white blood cell and platelet counts in human immunodeficiency virus--negative patients who are receiving multidrug regimens for pulmonary Mycobacterium avium complex disease

1 reference

12 December 2020

A four-year follow-up of patients with quiescent pulmonary tuberculosis at the end of a year of chemotherapy with twice-weekly isoniazid plus streptomycin or daily isoniazid plus pas

1 reference

12 December 2020

Experimental models to explain the high sterilizing activity of rifampin in the chemotherapy of tuberculosis

1 reference

12 December 2020

Minimal inhibitory concentrations of isoniazid, rifampin, ethambutol, and streptomycin against Mycobacterium tuberculosis strains isolated before treatment of patients in Taiwan

1 reference

12 December 2020

Rifapentine and isoniazid in the continuation phase of a 6-month regimen. Interim report: no activity of isoniazid in the continuation phase

1 reference

12 December 2020

Rifampicin-induced thrombocytopenia

1 reference

12 December 2020

CYP 3A proteins are expressed in human neutrophils and lymphocytes but are not induced by rifampicin

1 reference

12 December 2020

Rifabutin absorption in humans: relative bioavailability and food effect

1 reference

12 December 2020

Mechanism of the inhibitory effect of PAS granules on the absorption of rifampicin: Adsorption of rifampicin by an excipient, bentonite

1 reference

12 December 2020

Comparative effects of rifabutin and rifampicin on hepatic microsomal enzyme activity in normal subjects

1 reference

12 December 2020

Pharmacokinetics of rifampin under fasting conditions, with food, and with antacids

1 reference

12 December 2020

Rifapentine: its role in the treatment of tuberculosis

1 reference

12 December 2020

Effect of multiple doses of rifampin on the [14C N-methyl] erythromycin breath test in healthy male volunteers

1 reference

12 December 2020

Reduced plasma concentrations of antituberculosis drugs in patients with HIV infection

1 reference

12 December 2020

A pharmacokinetic study of intermittent rifabutin dosing with a combination of ritonavir and saquinavir in patients infected with human immunodeficiency virus

1 reference

12 December 2020

Controlled clinical trial of four short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis

1 reference

12 December 2020

Interaction of Ketoconazole with Rifampin and Isoniazid

1 reference

12 December 2020

Ritonavir enables combined therapy with rifampin and saquinavir

1 reference

12 December 2020

Rifampin and rifabutin and their metabolism by human liver esterases

1 reference

12 December 2020

Prevention and treatment of tuberculosis among patients infected with human immunodeficiency virus: principles of therapy and revised recommendations. Centers for Disease Control and Prevention

1 reference

12 December 2020

Global surveillance for antituberculosis-drug resistance, 1994-1997. World Health Organization-International Union against Tuberculosis and Lung Disease Working Group on Anti-Tuberculosis Drug Resistance Surveillance.

1 reference

12 December 2020

Pharmacokinetic study of the interaction between rifampin and delavirdine mesylate

1 reference

12 December 2020

Low antituberculosis drug concentrations in patients with AIDS.

1 reference

12 December 2020

Ranitidine--rifampicin interaction

1 reference

12 December 2020

Primary human hepatocytes as a tool for the evaluation of structure-activity relationship in cytochrome P450 induction potential of xenobiotics: evaluation of rifampin, rifapentine and rifabutin

1 reference

12 December 2020

Effectiveness of rifampin, rifabutin, and rifapentine for preventive therapy of tuberculosis in mice

1 reference

12 December 2020

Pharmacokinetics of antimycobacterial drugs in patients with tuberculosis, AIDS, and diarrhea

1 reference

12 December 2020

Saquinavir pharmacokinetics alone and in combination with nelfinavir in HIV-infected patients

1 reference

12 December 2020

Effect of clofazimine and dapsone on rifampicin (Lositril) pharmacokinetics in multibacillary and paucibacillary leprosy cases

1 reference

12 December 2020

Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: Prospective randomized comparison with parenteral therapy

1 reference

12 December 2020

Efficacy and safety of rifabutin in the treatment of patients with newly diagnosed pulmonary tuberculosis

1 reference

12 December 2020

Rifampicin raw material characteristics and their effect on bioavailability

1 reference

12 December 2020

The Garrod Lecture. Understanding the chemotherapy of tuberculosis--current problems

1 reference

12 December 2020

Acquired rifamycin monoresistance in patients with HIV-related tuberculosis treated with once-weekly rifapentine and isoniazid. Tuberculosis Trials Consortium

1 reference

12 December 2020

Urinary metabolites of rifabutin, a new antimycobacterial agent, in human volunteers

1 reference

12 December 2020

Bactericidal activity in vitro of various rifamycins against Mycobacterium avium and Mycobacterium tuberculosis

1 reference

12 December 2020

The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin

1 reference

12 December 2020

Standard short-course chemotherapy for drug-resistant tuberculosis: treatment outcomes in 6 countries

1 reference

12 December 2020

Induction of zidovudine glucuronidation and amination pathways by rifampicin in HIV-infected patients

1 reference

12 December 2020

Human serum attenuates the activity of protease inhibitors toward wild-type and mutant human immunodeficiency virus

1 reference

12 December 2020

Clinical Pharmacokinetics of Rifampicin

1 reference

12 December 2020

Consequences of rifampicin treatment on propafenone disposition in extensive and poor metabolizers of CYP2D6

1 reference

12 December 2020

HIV prevalence, immunosuppression, and drug resistance in patients with tuberculosis in an area endemic for AIDS

1 reference

12 December 2020

The early bactericidal activity of drugs in patients with pulmonary tuberculosis

1 reference

12 December 2020

Salivary levels of isoniazid and rifampicin in tuberculous patients

1 reference

12 December 2020

Alteration of ribosomes and RNA polymerase in drug-resistant clinical isolates of Mycobacterium tuberculosis

1 reference

12 December 2020

Phase I/II Study of the Toxicity, Pharmacokinetics, and Activity of the HIV Protease Inhibitor SC-52151

1 reference

12 December 2020

Using therapeutic drug monitoring to dose the antimycobacterial drugs

1 reference

12 December 2020

Acute hemolysis and renal failure following discontinuous use of rifampin

1 reference

12 December 2020

Rifampin in initial treatment of pulmonary tuberculosis. A U.S. Public Health Service tuberculosis therapy trial

1 reference

12 December 2020

Enzyme induction observed in healthy volunteers after repeated administration of rifapentine and its lack of effect on steady-state rifapentine pharmacokinetics: part I

1 reference

12 December 2020

Use of single sample clearance estimates of cytochrome P450 substrates to characterize human hepatic CYP status in vivo

1 reference

12 December 2020

Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.

1 reference

12 December 2020

A controlled comparison of two fully supervised once-weekly regimens in the treatment of newly diagnosed pulmonary tuberculosis

1 reference

12 December 2020

Induction and autoinduction properties of rifamycin derivatives: a review of animal and human studies

1 reference

12 December 2020

Controlled trial of intermittent regimens of rifampin plus isoniazid for pulmonary tuberculosis in Singapore. The results up to 30 months

1 reference

12 December 2020

Rifampicin plus isoniazid, rifampicin plus PAS, and isoniazid plus PAS in the initial treatment of pulmonary tuberculosis. A controlled multicenter clinical trial.

1 reference

12 December 2020

Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. Terry Beirn Community Programs for Clinical Research on AIDS, the Adult AIDS Clinical Trials Group, the Pan American He

1 reference

12 December 2020

Failure of ketoconazole treatment of Blastomyces dermatitidis [corrected] due to interaction of isoniazid and rifampin

1 reference

12 December 2020

Uptake of antibiotics by human alveolar macrophages.

1 reference

12 December 2020

Single and multiple dose pharmacokinetics of rifapentine in man: part II

1 reference

12 December 2020

The effect of pulsed exposures to rifampin on the uptake of uridine- 14 C by Mycobacterium tuberculosis

1 reference

12 December 2020

Development of rifapentine: the way ahead

1 reference

12 December 2020

Fixed-dose combination formulations for tuberculosis treatment

1 reference

12 December 2020

Comparison of azithromycin and clarithromycin in their interactions with rifabutin in healthy volunteers.

1 reference

12 December 2020

Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. Foreign-Body Infection (FBI) Study Group

1 reference

12 December 2020

Therapeutic drug monitoring in patients with cystic fibrosis and mycobacterial disease

1 reference

12 December 2020

Effect of rifampicin on the pharmacokinetics of itraconazole in normal volunteers and AIDS patients

1 reference

12 December 2020

Binding of rifampicin by human plasma proteins.

1 reference

12 December 2020

Comparison of Chinese and Western rifapentines and improvement of bioavailability by prior taking of various meals

1 reference

12 December 2020

Population pharmacokinetics of rifabutin in human immunodeficiency virus-infected patients

1 reference

12 December 2020

A comparison of two regimens for the treatment of Mycobacterium avium complex bacteremia in AIDS: rifabutin, ethambutol, and clarithromycin versus rifampin, ethambutol, clofazimine, and ciprofloxacin. Canadian HIV Trials Network Protocol 010 Study G

1 reference

12 December 2020

The value of in vitro drug activity and pharmacokinetics in predicting the effectiveness of antimycobacterial therapy: a critical review

1 reference

12 December 2020

Oral rifampin plus ofloxacin for treatment of Staphylococcus-infected orthopedic implants

1 reference

12 December 2020

Metabolism of rifabutin in human enterocyte and liver microsomes: kinetic parameters, identification of enzyme systems, and drug interactions with macrolides and antifungal agents

1 reference

12 December 2020

Comparison of activities of rifapentine and rifampin against Mycobacterium tuberculosis residing in human macrophages

1 reference

12 December 2020

Autoinduction of rifabutin metabolism in man.

1 reference

12 December 2020

Intraphagocytic penetration of antibiotics

1 reference

12 December 2020

Relationship of the manifestations of tuberculosis to CD4 cell counts in patients with human immunodeficiency virus infection

1 reference

12 December 2020

The effect of clofazimine on the pharmacokinetics of rifampicin and dapsone in leprosy

1 reference

12 December 2020

Adverse reactions to rifampicin in antituberculosis regimens

1 reference

12 December 2020

Evaluation of an intensive intermittent-induction regimen and duration of short-course treatment for human immunodeficiency virus-related pulmonary tuberculosis. Terry Beirn Community Programs for Clinical Research on AIDS (CPCRA) and the AIDS Clini

1 reference

12 December 2020

A controlled trial of daily and intermittent rifampicin plus ethambutol in the retreatment of patients with pulmonary tuberculosis: results up to 30 months

1 reference

12 December 2020

In vitro effect of alpha1-acid glycoprotein on the anti-human immunodeficiency virus (HIV) activity of the protease inhibitor CGP 61755: a comparative study with other relevant HIV protease inhibitors

1 reference

12 December 2020

Activity of two long-acting rifamycins, rifapentine and FCE 22807, in experimental murine tuberculosis

1 reference

12 December 2020

Rifampin-monoresistant tuberculosis in New York City, 1993-1994.

1 reference

12 December 2020

Pharmacokinetics of oral and intravenous rifampicin during chronic administration

1 reference

12 December 2020

Hypersensitivity reactions to rifampin. Pathogenetic mechanisms, clinical manifestations, management strategies, and review of the anaphylactic-like reactions

1 reference

12 December 2020

Pharmacogenetic determinants of codeine induction by rifampin: the impact on codeine's respiratory, psychomotor and miotic effects

1 reference

12 December 2020

Corneal endothelial deposits in children positive for human immunodeficiency virus receiving rifabutin prophylaxis for Mycobacterium avium complex bacteremia

1 reference

12 December 2020

Unusual pigmentation in patients with AIDS who are receiving rifabutin for bacteremia due to Mycobacterium avium/Mycobacterium intracellulare complex

1 reference

12 December 2020

Rifampicin-induced immune thrombocytopenia

1 reference

12 December 2020

U.S. Public Health Service Cooperative trial of three rifampin-isoniazid regimens in treatment of pulmonary tuberculosis

1 reference

12 December 2020

Drug malabsorption and resistant tuberculosis in HIV-infected patients.

1 reference

12 December 2020

Rifabutin. A review of its antimicrobial activity, pharmacokinetic properties and therapeutic efficacy

1 reference

12 December 2020

Malabsorption of antituberculosis medications by a patient with AIDS

1 reference

12 December 2020

Pharmacokinetic drug interactions with rifampicin

1 reference

12 December 2020

Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected patients taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors

1 reference

12 December 2020

Adverse Effects of Rifampin

1 reference

12 December 2020

Determination of in vitro susceptibility of mycobacteria to ansamycin

1 reference

12 December 2020

Pharmacokinetics of rifapentine in subjects seropositive for the human immunodeficiency virus: a phase I study

1 reference

12 December 2020

Risk factors for rifampin mono-resistant tuberculosis.

1 reference

12 December 2020

Relationships between exposure to saquinavir monotherapy and antiviral response in HIV-positive patients.

1 reference

12 December 2020

Update on rifampin drug interactions, III.

1 reference

12 December 2020

Does AIDS impair the absorption of antituberculosis agents?

1 reference

12 December 2020

10.2165/00003088-200140050-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

1 August 2017

1000972929

0 references

1 reference